[1]
Centers for Disease Control (CDC). Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep 1981; 30(21): 250-2522.
[2]
Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). Science 1983 May 20; 220(4599): 868-71.
[http://dx.doi.org/10.1126/science.6189183]
[http://dx.doi.org/10.1126/science.6189183]
[3]
Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984 May 4; 224(4648): 497-500.
[http://dx.doi.org/10.1126/science.6200935]
[http://dx.doi.org/10.1126/science.6200935]
[4]
Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984 May 4; 224(4648): 500-3.
[http://dx.doi.org/10.1126/science.6200936]
[http://dx.doi.org/10.1126/science.6200936]
[5]
Schüpbach J, Popovic M, Gilden RV, Gonda MA, Sarngadharan MG, Gallo RC. Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science 1984 May 4; 224(4648): 503-5.
[http://dx.doi.org/10.1126/science.6200937]
[http://dx.doi.org/10.1126/science.6200937]
[6]
Sarngadharan MG, Popovic M, Bruch L, Schüpbach J, Gallo RC. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 1984 May 4; 224(4648): 506-8.
[http://dx.doi.org/10.1126/science.6324345]
[http://dx.doi.org/10.1126/science.6324345]
[7]
Safai B, Sarngadharan MG, Groopman JE, et al. Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet 1984 June 30; 1(8392): 1438-40.
[http://dx.doi.org/10.1016/s0140-6736(84)91933-0]
[http://dx.doi.org/10.1016/s0140-6736(84)91933-0]
Related Books
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Anti-Infective Drug Discovery
Coronaviruses
Moving From COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences
COVID-19: Effects in Comorbidities and Special Populations
An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy
An Epidemiological Update on COVID -19
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Anti-infective Agents
Coronavirus Disease-19 (COVID-19): A Perspective of New Scenario
